Evolving Treatment Landscape of BTK Inhibitors in B-Cell Malignancies : Episode 5

Resistance to BTK Inhibitors in B-Cell Malignancies

Mar 4, 2019

Transcript:

Related Videos

Eunice Wang, MD

Expert on DLBCL

Tycel Phillips, MD

Tycel Phillips, MD, MPH

Tycel Phillips, MD

Expert on ALL

Thomas M. Habermann, MD

Thomas M. Habermann, MD

Thomas M. Habermann, MD

Related Content

Venetoclax Plus Obinutuzumab With or Without Ibrutinib Improves Undetectable MRD Rates in Fit Patients With CLL

FDA Approval Insights: Omidubicel in Blood Cancers Requiring Transplant

METTL3 Controls Splicing Factor Abundance and Aids Progression in CLL

FDA Approval Insights: Pirtobrutinib in MCL

February 27th 2023

OncLive Honors 12 Cancer Care Pioneers

Analysis Determines Predictive Biomarkers for Lenalidomide Survival Benefits in Mantle Cell Lymphoma

Venetoclax Plus Obinutuzumab With or Without Ibrutinib Improves Undetectable MRD Rates in Fit Patients With CLL

FDA Approval Insights: Omidubicel in Blood Cancers Requiring Transplant

METTL3 Controls Splicing Factor Abundance and Aids Progression in CLL

FDA Approval Insights: Pirtobrutinib in MCL

February 27th 2023

OncLive Honors 12 Cancer Care Pioneers

Analysis Determines Predictive Biomarkers for Lenalidomide Survival Benefits in Mantle Cell Lymphoma

Venetoclax Plus Obinutuzumab With or Without Ibrutinib Improves Undetectable MRD Rates in Fit Patients With CLL

FDA Approval Insights: Omidubicel in Blood Cancers Requiring Transplant

METTL3 Controls Splicing Factor Abundance and Aids Progression in CLL

FDA Approval Insights: Pirtobrutinib in MCL

February 27th 2023

OncLive Honors 12 Cancer Care Pioneers

Analysis Determines Predictive Biomarkers for Lenalidomide Survival Benefits in Mantle Cell Lymphoma

Related Content

Barbara Eichhorst, MD

Venetoclax Plus Obinutuzumab With or Without Ibrutinib Improves Undetectable MRD Rates in Fit Patients With CLL

Mitchell E. Horwitz, MD

FDA Approval Insights: Omidubicel in Blood Cancers Requiring Transplant

Yiming Wu, PhD

METTL3 Controls Splicing Factor Abundance and Aids Progression in CLL

Lori A. Leslie, MD

FDA Approval Insights: Pirtobrutinib in MCL

February 27th 2023

Ann H. Partridge, MD, MPH

OncLive Honors 12 Cancer Care Pioneers

Analysis Determines Predictive Biomarkers for Lenalidomide Survival Benefits in Mantle Cell Lymphoma

Analysis Determines Predictive Biomarkers for Lenalidomide Survival Benefits in Mantle Cell Lymphoma

Latest Conference Coverage

Medicaid Expansion Improves Survival in Pancreatic, Gastric Cancers, Potentially Reducing Disparities

Telephone-Based Weight Loss Program Is Effective for Breast Cancer Survivors

Pembrolizumab Plus Chemo With or Without Bevacizumab Maintains OS Benefit in Frontline Cervical Cancer

Minimally Invasive Distal Pancreatectomy Provides Effective Alternative in Resectable Pancreatic Cancer

View More Latest Conference Coverage

Editorial Board

CancerNetwork.com

OncNursingNews.com

TargetedOnc.com

Terms & Conditions

Do Not Sell My Information

Contact Info

2 Clarke Drive
Cranbury, NJ 08512

© 2023 MJH Life Sciences

All rights reserved.